证券代码：6 05016 证券简称：百龙创园 公告编号：2 024-0 4 8 山东百龙创园生物科技股份有限公司 关于向不特定对象发行可转换公司债券摊薄即期回报、 采取填补回报措施与相关主体承诺的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东百龙创园生物科技股份有限公司（以下简称"公司"）于 2024 年 9 月 20 日 召开第三届董事会第十二次会议，审议通过了关于向不特定对象发行可转换公司债券 的相关议案。根据《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护 工作的意见》《国务院关于进一步促进资本市场健康发展的若干意见》《关于首发及再 融资、重大资产重组摊薄即期回报有关事项的指导意见》等文件的有关规定，为保障 中小投资者知情权、维护中小投资者利益，公司就本次向不特定对象发行可转换公司 债券对即期回报摊薄的影响进行了分析，并结合实际情况提出了填补回报的相关措施， 相关主体对公司填补回报措施能够得到切实履行做出了承诺。具体情况如下： 一、本次可转债发行摊薄即期回报对公司主要财务指标的影响 （一）测算 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-046 山东百龙创园生物科技股份有限公司 2024 年半年度权益分派实施 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 每股分配比例 A 股每股现金红利 0.03 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/9/12 | － | 2024/9/13 | 2024/9/13 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 5 月 17 日的 2023 年年度股东大会审议授权董事会全权 办理中期利润分配相关事宜，经 2024 年 8 月 29 日的第三届董事会第十一次会议审议通过利 润分配方案。 二、 分配方案 1. 发放年度：2024 年半年度 2. 分派对象： 重要内容提示： 2. 自行发放对象 窦宝德、窦光朋 2 名股东所持股份的现金红利由公司自行发放。 ...

%% %% 丨证券研究报告丨 公司研究丨点评报告丨百龙创园（605016.SH） [Table_Title] 业绩持续增长，新产线即将放量 | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | 报告要点 | | | [Table_Summary] 公司发布 2024 年半年报，实现收入 5.3 亿元（同比 +28.7% ），实现归属净利润 1.2 亿元（同比 | | | +31.2% ），实现归属扣非净利润 1.1 亿元（同比 +31.0% ）。其中 Q2 单季度实现收入 2.8 亿元 （同比 +27.9% ，环比 +10.8% ），归属净利润 6602 万元（同比 +41.5% ，环比 +23.3% ），实现归 ...

华福证券 食品饮料 2024 年 09 月 03 日 司 研 百龙创园（605016.SH） 业绩高增盈利改善，产能扩充强化增长动能 事件：公司发布 2024 年半年报，2024 年 1-6 月公司实现营收 5.31 亿元， 同比+28.73%，归母净利润 1.20 亿元，同比+31.24%，扣非归母净利润 1.11 亿元，同比+31.04%；24Q2 实现营收 2.79 亿元，同比+27.93%，归母净利 润 0.66 亿元，同比+41.51%，扣非归母净利润 0.60 亿元，同比+35.87%。 益生元及膳食纤维拉动收入增长，Q2 境外收入实现快增 分产品看，24H1 公司益生元/膳食纤维/健康甜味剂/其他淀粉糖（醇）分别 实 现 收 入 1.53/2.88/0.60/0.03 亿 元 ， 同 比 +43.72%/+35.44%/-26.30%/ -56.63%，益生元及膳食纤维产品高增拉动收入快速增长；24Q2 则分别实 现收入 0.79/1.53/0.35/0.01 亿元，同比+34.42%/+37.78%/-19.03%/-62.35%， 健康甜味剂降幅环比收窄。分区域看，24H1 公司境内/境外分 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a revenue of 531 million yuan for H1 2024, representing a year-on-year increase of 28.73%, and a net profit attributable to shareholders of 120 million yuan, up 31.24% year-on-year [1] - The company achieved a record high quarterly revenue of 279 million yuan in Q2 2024, with a year-on-year growth of 27.93% [1] - The company has expanded its production capacity with the launch of new projects, which is expected to enhance revenue and profit growth in the second half of the year [1][2] Summary by Sections Financial Performance - For H1 2024, the company achieved a revenue of 531 million yuan, with a net profit of 120 million yuan and a non-recurring net profit of 111 million yuan, all showing significant year-on-year growth [1] - In Q2 2024, the company reported a revenue of 279 million yuan and a net profit of 66.02 million yuan, marking a year-on-year increase of 41.51% [1] - The gross margin for Q2 2024 was 33.22%, an increase of 2.14 percentage points year-on-year, supported by a favorable raw material cost environment and a higher proportion of high-margin products [1] Product and Regional Performance - The company’s revenue from its prebiotic series and dietary fiber series grew by 34.42% and 37.78% respectively in Q2 2024, contributing significantly to overall revenue growth [1] - Domestic and international revenues for Q2 2024 reached 114 million yuan and 166 million yuan, reflecting year-on-year growth of 12.2% and 41.6% respectively, with international growth providing substantial support [1] Capacity Expansion and Future Outlook - The company has completed the commissioning of a 30,000-ton dietary fiber and a 15,000-ton allulose project, which is expected to alleviate previous capacity constraints and boost revenue growth [1] - An investment of 212 million yuan has been announced for expanding the functional sugar drying project, which will further enhance product offerings and maintain long-term growth [1][2] - The company forecasts EPS of 0.85, 1.14, and 1.51 yuan for 2024-2026, maintaining a "Buy" rating based on expected continued high growth [2]

关于 2024 年半年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●每股分配比例及转增比例：A 股每 10 股派发现金红利 0.30 元（含税）。 ●以未来实施本次分配方案时股权登记日的公司总股本为基数，具体日期将 在权益分派实施公告中明确。 证券代码：605016 证券简称：百龙创园 公告编号：2024-040 山东百龙创园生物科技股份有限公司 一、利润分配预案内容 山东百龙创园生物科技股份有限公司（以下简称"公司"）2024 年半年度合 并报表归属于上市公司股东的净利润 11,956.23 万元，公司母公司累计未分配利 润为 71,717.70 万元，上述数据未经审计。考虑公司所处经营发展阶段及未来资 金需求，公司 2024 年半年度利润分配方案如下： 拟以未来实施本次利润分配方案时股权登记日的总股本为基数，向全体股东 每 10 股派发现金红利人民币 0.30 元（含税）。截至 2024 年 6 月 30 日，公司总 股本为 323,086,400 股，以此为基数测算，合计拟 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-045 山东百龙创园生物科技股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2024 年 09 月 19 日(星期四) 上午 09:00-10:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 09 月 10 日(星期二) 至 09 月 18 日(星期三)前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 blcyzqb@sdblcy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 山东百龙创园生物科技股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年度报告，为便于广大投资者 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-041 山东百龙创园生物科技股份有限公司 关于投资建设"功能糖干燥扩产与综合提升项目" 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 重要内容提示： （一）本项目尚需获得相关政府部门审批，能否获得批准尚存在不确定性； （二）项目建设期间可能受宏观经济形势等因素影响，影响项目建设进展及 收益，存在一定项目风险； （三）本项目具有一定的建设周期，如未来市场情况发生变化将会对公司收 入、利润水平的实现造成不确定性影响。敬请广大投资者理性投资，注意风险。 一、投资项目概述 （一）投资项目的基本情况 公司拟投资 21,160.74 万元建设"功能糖干燥扩产与综合提升项目"。项 目拟新建生产车间和干燥车间，总占地面积为 5,400.00m 2，总建筑面积为 16,200.00m2，其中生产车间建筑面积 3,600.00m 2，干燥车间为 12,600.00m2。项 目建成后年可生产 11,000 吨异麦芽酮糖、1,800 吨低聚半乳糖和 200 吨乳果糖 产品。 ...

Financial Performance - The company achieved total operating revenue of ¥531,348,371.43, representing a year-on-year growth of 28.73%[18]. - The net profit attributable to shareholders was ¥119,562,324.06, an increase of 31.24% compared to the same period last year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥111,313,666.15, up 31.04% year-on-year[18]. - The net cash flow from operating activities was ¥99,241,327.69, a decrease of 3.74% due to increased raw material payments[18]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,567,743,151.18, reflecting a growth of 3.97%[18]. - Total assets increased by 8.49% to ¥1,903,166,060.27 compared to the end of the previous year[18]. - The basic earnings per share remained at ¥0.37, with diluted earnings per share also at ¥0.37[17]. - The weighted average return on equity increased by 1.08 percentage points to 7.63%[17]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares, totaling RMB 9,692,592.00, which accounts for 8.11% of the net profit attributable to shareholders for the year[3]. Market and Product Development - The company focuses on the development of prebiotics, dietary fibers, and healthy sweeteners, which are expected to drive future growth[22]. - The prebiotic market in China is projected to reach a total output value of ¥3.624 billion by 2025, with global output expected to reach ¥18.047 billion[22]. - The dietary fiber industry in China is projected to reach a total output value of 5.527 billion yuan by 2026, while the global market is expected to reach 22.913 billion yuan[23]. - The company produces a range of health sweeteners, primarily allulose, which is a rare monosaccharide with a caloric content significantly lower than sucrose, making it ideal for obesity and diabetes patients[24]. - The company is one of the few in the industry capable of large-scale production of over 90 different functional food ingredient products, positioning itself as a leading manufacturer globally[25]. Production and Operational Efficiency - The company employs a flexible production model that allows for rapid adjustments to product types and specifications based on market demand, ensuring efficient resource utilization[28]. - The company has established a fully automated production line that allows for flexible production, maximizing efficiency by producing different categories and models of products on the same line[35]. - The company has completed the construction of a 30,000-ton soluble dietary fiber project and a 15,000-ton crystalline sugar project, both of which are now fully operational[48]. Research and Development - The company aims to develop 5-6 new product specifications annually and launch 2-3 new products to meet diverse customer needs, with recent developments including sugar-free resistant dextrin and high DE resistant dextrin[38]. - Research and development expenses rose by 32.17% to ¥18,872,642.21 from ¥14,279,511.10, driven by increased project development activities[56]. Environmental and Regulatory Compliance - The company has implemented green manufacturing technology innovations to improve carbon reduction capabilities and enhance its green manufacturing capacity[37]. - The company has been recognized as a green factory in Shandong Province and on the national green factory list, demonstrating positive social effects[82]. - The company emphasizes continuous investment in environmental protection and pollution control measures to meet increasing regulatory standards[80]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[78]. Shareholder and Governance Matters - The company’s major shareholders have committed to not transferring or managing their shares for 36 months post-IPO, with specific conditions for share transfers thereafter[84]. - The company’s directors and senior management have also committed to a 12-month lock-up period for their shares post-IPO, with similar transfer conditions[86]. - The company will publicly apologize and compensate for any losses incurred due to non-compliance with share lock-up commitments[85][88]. - The company has established measures to reduce and regulate related party transactions, ensuring fairness and compliance with market principles[93]. Financial Position and Assets - The total assets at the end of the reporting period included cash and cash equivalents of ¥206,790,815.75, a 17.58% increase from ¥175,871,524.33[57]. - The company’s fixed assets increased significantly by 164.98% to ¥874,036,474.45, primarily due to the completion of new projects[57]. - The company reported a significant increase in cash and cash equivalents, contributing to improved liquidity[116]. Risk Management - The company faces risks related to raw material price fluctuations, which could significantly impact product costs and profit margins due to delayed adjustments in sales prices[69]. - The company is exposed to exchange rate risks due to its increasing export volume settled in USD, which may affect its financial performance[70]. Legal and Compliance - The company confirmed that the merger cost for non-similar control mergers is based on the fair value of assets, liabilities, and equity securities at the acquisition date[144]. - The company has not reported any violations or penalties against its directors, supervisors, or senior management during the reporting period[99].

根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之 《第十四号——食品制造》相关规定，现将山东百龙创园生物科技股份有限公司 （以下简称"公司"）2024 年半年度主要经营数据（未经审计）公告如下： 一、公司 2024 年半年度主要经营数据 2024 年 1-6 月，公司实现营业总收入 53,134.84 万元，同比增长 28.73%； 实现归属于上市公司股东的净利润 11,956.23 万元，同比增长 31.24%。实现主 营业务收入为 50,344.46 万元，同比增长 23.78%。主营业务收入构成情况具体 如下： | 项目 | 2024 年 1-6 | 月 | 2023 年 | 1-6 月 | | --- | --- | --- | --- | --- | | | 金额（万元） 比例（%） | | 金额（万元） 比例（%） | | | 益生元系列 | 15,263.82 | 30.32 | 10,620.86 | 26.11 | | 膳食纤维系列 | 28,816.95 | 57.24 | 21,276.90 | 52.31 | | 健康甜味剂系列 | 5,973.71 | 11.8 ...